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Abstract
Because of similarities in histopathology and tumor
progression stages between mouse and human lung
adenocarcinomas, the mouse lung tumor model with
lung adenomas as the endpoint has been used exten-
sively to evaluate the efficacy of putative lung cancer
chemopreventive agents. In this study, a competitive
cDNA library screening (CCLS) was employed to deter-
mine changes in the expression of mRNA in chemically
induced lung adenomas compared with paired normal
lung tissues. A total of 2555 clones having altered
expression in tumors were observed following compet-
itive hybridization between normal lung and lung ade-
nomas after primary screening of over 160,000 clones
from a mouse lung cDNA library. Among the 755 clones
confirmed by dot blot hybridization, 240 clones were
underexpressed, whereas 515 clones were overex-
pressed in tumors. Sixty- five clones with the most fre-
quently altered expression in six individual tumors were
confirmed by semiquantitative RT-PCR. When examin-
ing the 58 known genes, 39 clones had increased ex-
pression and 19 had decreased expression, whereas the
7 novel genes showed overexpression. A high percen-
tage (>60%) of overexpressed or underexpressed
genes was observed in at least two or three of the le-
sions. Reproducibly overexpressed genes included
ERK-1, JAK-1, surfactant proteins A, B, and C, NFAT1,
A -1 protease inhibitor, helix–loop–helix ubiquitous
kinase (CHUK), A-adaptin, A-1 PI2, thioether S-methyl-
transferase, and CYP2C40. Reproducibly underex-
pressed genes included paroxanase, ALDH II, CC10,
von Ebner salivary gland protein, and A - and B -globin.
In addition, CCLS identified several novel genes or
genes not previously associated with lung carcinoge-
nesis, including a hypothetical protein (FLJ11240) and a
guanine nucleotide exchange factor homologue. This
study shows the efficacy of this methodology for iden-
tifying genes with altered expression. These genes may
prove to be helpful in our understanding of the genetic
basis of lung carcinogenesis and in developing biomar-
kers for lung cancer chemoprevention studies in mice.
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Introduction
Lung cancer is the leading cause of cancer deaths in men and
women in the US [1]. Epidemiological and laboratory animal
model studies have demonstrated that smoking and envi-
ronmental exposure to carcinogens are closely linked to in-
creased lung cancer risk [1–5]. Although about half of all
people who had ever smoked are now former smokers,
many people are unable or unwilling to stop smoking. For
these reasons, chemoprevention is a potentially important
approach to reduce the large number of tobacco-caused
cancer deaths, especially for former smokers. The A/J
mouse lung tumor model, primarily adenomas, is the most
widely used preclinical model for lung cancer chemopreven-
tion studies [3,6 ]. In addition to similarity between adeno-
mas/adenocarcinomas commonly seen in mice and human
lung adenocarcinomas, genetic changes found in mouse lung
tumors also resemble those existing in humans [3,6 ]. Among
the more than 50 different agents tested, several groups of
chemicals have shown significant efficacy against mouse
lung tumor development including glucocorticoids, green tea,
nonsteroidal anti - inflammatory drugs (NSAIDs), isothiocya-
nates, and farnesyl transferase inhibitors [3 ].
Genetic changes found in mouse lung tumors include
mutational activation of the K- ras gene, which is observed
in 80% of both spontaneously occurring and chemically in-
duced adenomas and adenocarcinomas of the mouse lung
[3,7]. Mutation of K- ras is an early event in mouse lung
tumorigenesis and persists into malignancy [3,7 ]. Aberrant
expression of other oncogenes or tumor suppressor genes,
e.g., c -myc,Rb, and p16 genes, has also been demonstrated
in mouse lung tumorigenesis [8]. Allelic deletions on different
chromosomes suggest the involvement of additional known
and unknown genes during mouse lung tumorigenesis. Allelic
loss of the p16 tumor suppressor gene occurs in approx-
imately 50% of mouse lung adenocarcinomas [9]. Allelic loss
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of chromosomes 1, 4, 11, 12, and 14 are frequently as-
sociated with mouse lung tumor development [9–11]. Re-
cently, mouse lung tumor susceptibility loci have been
mapped to chromosomes 6, 9, 17, and 19. Those linked to
lung tumor resistance have been mapped to chromosomes
4, 11, 12, and 18 [3].
Detection of mutations or LOH in specific oncogenes and
tumor suppressor genes has been the focus in examining for
genetic alterations in tumors. More global methods have
recently been developed. These include CGH analysis,
which allows one to examine for gene deletion or ampli-
fication, and proteomics, which allows determination of
protein levels. The use of cDNA microarrays to detect al-
tered gene expression during the neoplastic process has
perhaps generated the greatest amount of effort to date. In
particular, high-density oligonucleotide arrays and high-
density cDNA glass slide arrays have been widely used in
profiling gene expression in human and rodent tumor tis-
sues. In the present study, we have used competitive
cDNA library screening (CCLS) [12]. CCLS allows one to
screen in a nonselective manner for known or unknown
genes whose expression is altered between two sets of
samples [12] by performing a competitive hybridization
between normal lung and lung adenomas and by screening
this against cDNA clones generated from normal lung.
Employing this technology, we identified 65 distinct genes
(58 known and 7 novel ) whose expression is routinely al-
tered in mouse lung adenomas.
Materials and Methods
Lung Adenomas
At 6 weeks of age, female A/J mice received a single
intraperitoneal ( i.p. ) injection of N -methyl -N -nitrosourea
(MNU) in acidified saline (pH 5.0) at a dose of 50 mg/kg
body weight. The mice were terminated at 6 months of age
and the adenomas and paired normal tissues were har-
vested and frozen in liquid nitrogen for RNA analysis. All lung
tumors used from this lung tumor bioassay were diagnosed
as lung adenomas. Lung adenomas were carefully micro-
dissected before they were used for RNA isolation. Briefly,
frozen tumor tissues were microdissected to determine the
borders of tumor versus normal tissues. Tissues were em-
bedded in Tissue Tek OCT compound (VWR Scientific Pro-
ducts, West Chester, PA), cryostat -sectioned, and stained
with hematoxylin and eosin for microscopy. Tumor tissue
sections corresponding to the microscopic sections contain-
ing only tumor cells were isolated and stored at 808C for
subsequent RNA isolation. Matching normal tissues from the
same animal were also microdissected to ensure that
specimens consisted of purely normal lung tissue.
Isolation of RNA
Total RNA from tumors and paired surrounding normal
tissue was isolated from pulverized tissues (normal / tumor)
according to an acid–guanidine–thiocyanate–phenol–chlo-
roform method described previously [12]. The quantity and
purity of the RNA were determined by spectrophotometry
at wavelengths of 260/280 nm, and the RNA quality was
checked by electrophoresis on a formaldehyde agarose gel.
Labeling cDNA Probes by Reverse Transcription (RT)
Two micrograms of total RNA and 2 l of oligo (dT) 15
primer (500 g/ml) (Promega, Madison, WI) mix were
incubated at 658C for 5 minutes, and then chilled on ice.
Other reagents were added in a total of 25 l of reaction
volume containing 1 RT buffer (50 mM Tris–HCl, pH 8.3;
75 mM KCl; 3 mM MgCl2; 10 mM DTT; 0.2 mg/ml BSA);
1.0 mM dTTP, dATP, and dGTP; and either 100 Ci of
[a -32P]dCTP or 1.0 mM cold dCTP; 100 U RNasin (Pro-
mega); and 200 U of M-MLV reverse transcriptase (GIBCO
BRL/Life Technology, Gaithersburg, MD). The reaction mix-
tures were incubated at 378C for 1 hour. The probes were
purified by Sephadex G-50 Columns (Boehringer Mann-
heim, Indianapolis, IN) and the specific labeling activity
was determined by liquid scintillation counting. Specifically,
for hybridization probe set 1, 2 g of total RNA from a mouse
lung adenoma was reverse- transcribed with [a - 32P]dCTP
for direct incorporation. The labeled tumor cDNA probe was
then mixed with equal amount of unlabeled cDNA and 5 g of
mouseCotI DNA, then denatured at 958C for 10 minutes. For
hybridization probe set 2, 2 g of total RNA from the paired
normal lung was reverse- transcribed with [a -32P] dCTP for
direct incorporation. The labeled normal cDNA probe was
then mixed with equal amount of unlabeled cDNA and 5 g of
mouse CotI DNA and denatured.
cDNA Libraries as Targets for Competitive Hybridization
Uni-ZAP XR mouse lung cDNA library, purchased from
Stratagene (La Jolla, CA), was used as the target for CCLS.
Approximately 1.6105 plaques were plated in 200 Petri
dishes (100 mm) and then transferred to nitrocellulose filters
following the protocol provided by the supplier. Two identical
filters were made from each plate and the plaque DNA on
these filters was denatured in 1.5 M NaCl /0.5 N NaOH,
neutralized in 2.5 M NaCl/1 M Tris (pH 7.4), rinsed in 3
SSC, and baked at 808C for 2 hours. After 12 hours of
prehybridization with hybridization solution, one replica was
hybridized to labeled tumor probe with an unlabeled com-
petitor (set 1), whereas the other was hybridized to labeled
normal probe with the same nonlabeled competitor (set 2).
Hybridization solution consisted of 50% formamide, 5
SSPE, 5 Denhardt’s solution, 0.1% SDS, and 100 g/ml
denatured herring sperm DNA. The hybridization was
performed at 428C for 18 hours with mild rolling or shaking.
Membranes were stringently washed with agitation in 2
SSC/0.1% SDS twice (10 minutes each) at room temper-
ature and 30 minutes in 0.1 SSC/0.1% SDS twice at 658C.
Dried filters were exposed to X-ray film for 3 to 15 days at
room temperature.
Reverse Dot Blot Analysis
Positive clones found in the CCLS primary screening
were verified by reverse dot blot analysis that served as a
secondary screen to eliminate false positives. DNA from
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positive clones was isolated using the standard mini prep
method described previously [12]. DNA was denatured by
adding 0.1 vol of 2 N NaOH, 2 mM EDTA at 378C for 30
minutes and neutralized with 0.1 vol of 3 M sodium acetate
(pH 4.8). Two micrograms of denatured DNA was then
spotted onto nylon membranes using the HYBRI.DOT
Manifold Apparatus (GIBCO BRL/Life Technology). Du-
plicate membranes were prepared for each clone. These
membranes were hybridized with probes prepared as des-
cribed above for the CCLS primary screening. The washing
conditions were also the same as above.
DNA Sequence Analysis
Differentially expressed clones as identified by dot blot
analyses were selected for sequencing using vector-specific
primers. Cycling sequencing with Taq polymerase was
performed with fluorescent - labeled dideoxynucleotides
(BigDye Terminator DNA Sequence Kit; PE Applied Bio-
systems, Forster City, CA) with phagmid DNA as template
according to the manufacturer’s instructions. After the
reaction, the samples were resolved on an ABI fluorescent
DNA sequencer. GenBank database matching was per-
formed with BLAST sequence comparison programs at NCBI
(http: / /www.ncbi.nlm.nih.gov /blast ).
Gene-Specific Quantitative RT-PCR Analysis
Two micrograms of total RNA was used to synthesize
cDNA in a total volume of 30 l. After incubation of the RNA
in 19 l of DEPC-treated water at 658C for 10 minutes, the
following components were added: 1 l of 45 nM oligo-dT,
5 reaction buffer (50 mM Tris–HCl, pH 8.3, 75 mM KCl),
0.6 l of 50 U/l RNase inhibitor, and 2 l of 200 U/l M-
MLV reverse transcriptase. The reaction mixture was incu-
bated at 378C for 1 hour. The reaction was then terminated at
958C for 10 minutes. We performed comparative multiplex
PCR to semiquantitatively evaluate the gene expression
differences. In comparative multiplex PCR, primer pairs from
the control cDNA, GAPDH, and the target gene cDNA would
be included in each reaction at equivalent concentrations.
The coamplification of the control cDNA and the target gene
cDNA in tumor and normal tissues would provide a means to
control for PCR amplification and enable the relative level of
the target gene expression to be quantified. A pair of primers
specific for mouse GAPDH cDNA was used as an internal
control. Prior to PCR, one primer from each pair (GAPDH
and target gene) was 50 end- labeled with T4 polynucleotide
kinase (United States Biochemical, Cleveland, OH). Forty
picomoles of each target primer pair and GAPDH primer pair
was then combined with 1 l of aliquot of cDNA, 100 M of
each deoxyribonucleotide (dATP, dCTP dGTP, and dTTP),
1.0 U of Taq DNA polymerase (Promega, Madison, WI),
50 mM KCl, 10 mM Tris–HCl (pH 9.0), and 0.1% Triton
X-100. A reaction volume of 20 l is subjected to 18 to
24 cycles of PCR amplification. Each cycle consisted of
1 minute at 948C, 2 minutes at 57 to 608C, and 1 min at
728C. To determine the linear range of each PCR reactions,
a series of three to four PCR reactions using 18, 20, 22, or 24
cycles were performed for each target gene, and one of the
reactions that fits into the linear range was used for further
quantitation. Approximately 2.5 l of reaction mixture from
each PCR was loaded on the 8% polyacrylamide gel and run
at 60 W for about 2 hours. Gels were dried and exposed to a
Phosphor Image screen for 48 hours. The signals collected
by the screen were analyzed by computer software Image-
Quant Version1.1. The relative intensities of the target
products were then normalized to the level of GAPDH
control. The normalized intensities of normal lung tissues
and those of tumors were compared to assess for gene
expression differences. For hard copy of the image, dried
gels were also exposed to X-ray films overnight.
Statistical Analysis
After normalization to the level of GAPDH cDNA ampli-
fication in the multiplex PCR reactions using cDNA from both
normal lungs and lung adenomas, Student’s t test was used
to determine the difference in the signal intensity of phosphor
imaging between normal lungs and lung adenomas.
Results
Six pairs of lung adenomas and normal lung tissues were
used in the primary screening to detect differentially
expressed genes. Lung adenomas were obtained from A/J
mice using a standard 6-month protocol employing MNU as
the carcinogen. As shown in Figure 1, lung adenomas used
in the present study are characterized by a monomorphic
growth pattern and are generally comprised of well -differ-
entiated pulmonary cells. A total of 200 pairs of nitrocellulose
filters, containing nearly 1.6105 clones from a mouse lung
cDNA library, were screened with two sets of labeled cDNA
probes (Figure 2, A and B ). One set was a mixture from a
[a -32P]dCTP labeled cDNA derived from an MNU- induced
lung adenoma and unlabeled DNA derived from a normal
paired lung. The other set was prepared from mixture of a
[a -32P]dCTP labeled cDNA from a normal paired lung and a
Figure 1. Histology of a normal lung and a lung adenoma used in this study.
Light photomicrographs of a normal lung (A and B ) and a lung adenoma (C
and D) at 4 and 40 magnifications, respectively.
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nonlabeled cDNA prepared from an equal amount of total
RNA from normal lung tissue. Approximately 2500 clones
were found to have substantially altered expression in
mouse lung tumors. These clones underwent secondary
screening by reverse dot blot analysis to eliminate the false-
positive clones (Figure 2C ). Sequence analysis was
performed on 755 clones confirmed by dot blot analysis,
and the sequences were entered into BLAST of National
Center for Biotechnology Information (NCBI) to search for
matches in the GenBank database. The results of the
BLAST search showed that many of the 755 clones matched
to the mouse Clara cell 10-kDa (CC10) protein (197) or
the surfactant protein C (371), reflecting their high ex-
pression resulting in multiple independent clones in the
non-normalized mouse lung cDNA library employed for
CCLS analysis.
Figure 2. Analysis of differentially expressed genes in mouse lung adenomas using CCLS. (A ) Schematic illustration of CCLS. Equal amounts of total RNA from
lung tumors and normal tissues were converted to cDNA probes with incorporation of 32P into the cDNA strands during RT. Two competitors were also generated
from normal lung tissues using the same procedure except for 32P incorporation. Probes 1 and 2 were used to perform differential hybridization against a mouse lung
cDNA library. (B ) An example of data from CCLS. Two identical filters were differentially hybridized with the cDNA probes. The left one represents hybridization with
the probe generated from normal tissue, whereas the right one represents hybridization with the probe derived from a lung tumor. The three spots indicated by arrows
show three differentially expressed clones that were identified by CCLS. (C ) Results of dot blot analysis. Dot blot analysis was conducted as one confirmation step.
Differentially expressed clones selected from CCLS were confirmed by dot blot analysis. The GAPDH was used as an internal control.
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In order to confirm differential mRNA expression, 83
distinctive clones were further examined by quantitative
RT-PCR analysis in duplicate to avoid false positives
(Figure 3). Detected genes were divided into two categories:
overexpressed and underexpressed in tumors compared
with their paired normal tissues (Table 1). We confirmed 65
of 83 selected clones by quantitative RT-PCR (Table 1).
Secondary confirmation of differential gene expression in
lung adenomas by Northern blot analysis could not be
performed due to the limited amount of RNA from the
individual adenomas employed in the present study.
Nineteen genes were underexpressed, whereas 46 genes
were overexpressed in lung tumors. Fifty -eight genes
showed high homology (greater than 90%) to known genes,
and seven genes, which did not match any known genes
in the NCBI sequence database, were considered to be
novel (see Table 2). Three genes, which showed lower
homology to known genes, were human TNFa -stimulated
ABC protein, human KIAA0187, and a human homolog of
Drosophila melanogaster flightless I, which had 81%, 85%,
and 87% homology, respectively.
In examining the genes with altered expression, we
found consistency in the alterations. Thus, of the 46 genes
that were overexpressed, 35 were overexpressed in at least
two or three of tumors and 30 were overexpressed in more
than 80% of tumors. The degree of overexpression, even
among consistently overexpressed genes, varied from gene
to gene. For example, ERK-1 was increased in four of six
tumors but by an average of only two- fold, whereas JAK-1
was increased in six of six tumors by an average of roughly
eight- fold. Similarly, the TNFa -stimulated ABC protein was
decreased in three of six tumors by roughly two- fold, where-
as the paroxanase gene (PON-1 ) was decreased roughly
six- fold in six of six tumors.
Genes that were overexpressed in lung adenomas are
also shown in Table 1. Thirty -nine overexpressed genes had
high homology to known genes, whereas seven showed li-
mited homology and were designated as unknown genes.
Six of the unknown genes (LRG1, LRG3, LRG4, LRG5,
LRG6, and LRG7 ) were highly overexpressed in 100% of
lung tumors (Tables 1 and 2). This consistent and high
overexpression makes them potentially interesting candi-
dates as tumor cell markers for diagnosis and early detection
as well as potential targets for chemoprevention or chemo-
therapy studies using mouse lung tumor models. In addition,
19 genes were found to be underexpressed in lung ade-
nomas, with six showing underexpression in at least 80% of
adenomas. Other underexpressed genes include RasGAP,
a -globin, b -globin, paroxanase (PON-1 ), carbonic anhy-
drase (CA) IV, Clara cell 10-kDa protein (CC10), ALDH II,
growth factor– inducible immediate-early gene (cyr61 ), and
human TNFa -stimulated ABC protein were absent or down-
regulated in mouse lung tumors. Specific genes that were
overexpressed in lung tumors include ERK-1, JAK-1, SPI6,
fibrinogen A a -chain, surfactants A, B, and C, MCH class I
heavy chain, NFAT1 isoform A, sulfated glycoprotein-2, zinc
finger protein, helix– loop–helix ubiquitous kinase (CHUK ),
a -1PI -2, a -adaptin, thioether S -methyltransferase, human
putative transcription factor CA150, C3, CYP2C40, and so
forth (Table 1).
Two of the genes were further characterized through
extensive sequencing and comparison of both mouse and
human cDNA: a hypothetical protein (FLJ11240) and a
guanine nucleotide exchange factor (GEF) homologue
(Figure 4). FLJ11240 hypothetical protein was found to
have limited homology with a peptidase, E1–E2 ATPase,
His kinase, and Ppx/GppA phosphatase when searching
the Protein-BLAST database (NCBI, NIH). The GEF gene
Figure 3. RT-PCR verification of differentially expressed genes detected using CCLS. ‘‘N’’ represents the normal mouse lung tissue; ‘‘T’’ represents the MNU-
induced mouse lung adenomas. GAPDH was applied as an internal control to determine the amount of template in each reaction. (A ) RT -PCR confirmation of
upregulated genes. Zfp96, zinc finger protein 96; CHUK, conserved helix – loop–helix ubiquitous kinase; SP -A, surfactant protein A; and JAK1 protein. (B ) RT -
PCR confirmation of downregulated genes. Cry61, growth factor – inducible immediate early gene; CC10, Clara cell protein 10; Emb11, 11 - day embryo cDNA; and
CA IV, carbonic anhydrase IV.
Neoplasia . Vol. 5, No. 1, 2003
Expression Profile in Mouse Lung Adenomas Yao et al. 45
T
a
b
le
1
.
R
T
-P
C
R
C
o
n
fir
m
e
d
G
e
n
e
s
w
ith
D
iff
e
re
n
tia
l
E
x
p
re
s
s
io
n
in
M
o
u
s
e
L
u
n
g
A
d
e
n
o
m
a
s
U
s
in
g
C
C
L
S
.
G
e
n
e
y
U
p
re
g
u
la
tio
n
G
e
n
e
y
D
o
w
n
re
g
u
la
tio
n
In
c
id
e
n
c
e
z
C
h
a
n
g
e
s
(f
o
ld
)x
N
o
rm
a
l
(m
e
a
n
±
S
D
)
T
u
m
o
r
(m
e
a
n
±
S
D
){
In
c
id
e
n
c
e
z
C
h
a
n
g
e
s
(f
o
ld
)x
N
o
rm
a
l
(m
e
a
n
±
S
D
)
T
u
m
o
r
(m
e
a
n
±
S
D
){
m
R
N
A
fo
r
tr
a
n
s
la
tio
n
a
l
c
o
n
tr
o
lle
d
4
0
-k
D
a
p
o
ly
p
e
p
tid
e
p
4
0
2
/6
2
–
3
0
.7
3
2
±
0
.0
0
2
1
.5
8
4
±
0
.0
1
3
**
1
0
-D
a
y
-o
ld
m
a
le
p
a
n
c
re
a
s
c
D
N
A
3
/6
2
–
4
3
.3
2
2
±
0
.5
0
6
1
.2
6
0
±
0
.4
4
3
*
H
o
m
o
p
u
ta
tiv
e
tr
a
n
s
c
ri
p
tio
n
fa
c
to
r
C
A
1
5
0
4
/6
3
–
5
0
.0
4
6
±
0
.0
0
2
0
.1
9
4
±
0
.0
5
5
*
1
1
-D
a
y
e
m
b
ry
o
c
D
N
A
5
/6
2
–
4
4
.7
6
8
±
0
.4
1
0
1
.6
9
3
±
0
.5
4
6
**
4
5
S
p
re
-r
R
N
A
5
/6
2
–
7
2
3
.3
1
±
3
.2
2
5
7
9
.6
7
±
3
4
.8
5
*
1
3
-D
a
y
e
m
b
ry
o
liv
e
r
c
D
N
A
3
/6
2
–
5
1
0
.6
6
±
1
.7
2
1
3
.3
9
9
±
1
.2
2
7
*
m
R
N
A
fo
r
c
y
s
te
in
y
l-
tR
N
A
s
y
n
th
e
ta
s
e
6
/6
2
–
6
0
.0
1
7
±
0
.0
0
1
0
.0
7
1
±
0
.0
2
7
**
a
-G
lo
b
in
m
R
N
A
4
/6
2
–
3
5
.7
3
1
±
0
.0
1
1
2
.6
4
3
±
0
.3
5
5
**
*
m
R
N
A
fo
r
p
a
n
c
o
rt
in
-1
a
n
d
-3
6
/6
2
–
3
0
.0
1
4
±
0
.0
0
3
0
.0
3
6
±
0
.0
1
0
**
b
-G
lo
b
in
m
a
jo
r
g
e
n
e
6
/6
2
–
4
6
.6
2
3
±
0
.1
8
6
2
.3
1
7
±
0
.6
0
2
**
*
S
e
ri
n
e
h
y
d
ro
la
s
e
-l
ik
e
(S
e
rh
l)
m
R
N
A
4
/6
2
–
3
0
.0
2
5
±
0
.0
0
4
0
.0
6
5
±
0
.0
1
8
*
C
A
IV
g
e
n
e
3
/6
3
–
4
0
.1
2
7
±
0
.0
0
7
0
.0
4
3
±
0
.0
0
6
**
*
H
u
m
a
n
h
y
p
o
th
e
tic
a
l
p
ro
te
in
F
L
J
1
1
2
4
0
3
/6
2
0
.0
2
6
±
0
.0
0
7
0
.0
5
7
±
0
.0
2
0
*
A
L
D
H
II
m
R
N
A
5
/6
2
–
5
0
.5
7
5
±
0
.0
7
6
0
.1
8
3
±
0
.0
6
3
*
G
e
n
e
fo
r
fib
ri
n
o
g
e
n
A
-a
-c
h
a
in
3
/6
2
–
8
0
.0
4
0
±
0
.0
0
2
0
.1
7
9
±
0
.0
0
2
**
G
ro
w
th
fa
c
to
r–
in
d
u
c
ib
le
im
m
e
d
ia
te
-e
a
rl
y
g
e
n
e
,
c
y
r6
1
5
/6
3
–
1
0
0
.3
7
9
±
0
.0
9
3
0
.0
5
5
±
0
.0
1
8
*
m
R
N
A
fo
r
e
rk
-1
4
/6
2
–
3
0
.2
8
6
±
0
.0
3
8
0
.5
6
6
±
0
.0
5
4
**
*
P
a
ro
x
a
n
a
s
e
(P
O
N
-1
)
m
R
N
A
6
/6
4
–
1
0
0
.3
7
9
±
0
.0
9
3
0
.0
4
6
±
0
.0
2
7
*
J
A
K
-1
p
ro
te
in
6
/6
3
–
1
0
0
.0
2
9
±
0
.0
1
0
0
.1
5
3
±
0
.0
1
9
**
H
o
m
o
s
a
p
ie
n
s
g
lu
c
o
s
e
-r
e
g
u
la
te
d
p
ro
te
in
2
/6
2
0
.2
5
4
±
0
.0
1
2
0
.1
3
0
±
0
.0
0
7
*
N
e
u
ro
n
a
l
g
u
a
n
in
e
n
u
c
le
o
tid
e
e
x
c
h
a
n
g
e
fa
c
to
r
6
/6
3
–
9
0
.0
1
6
±
0
.0
0
2
0
.0
7
5
±
0
.0
3
7
**
H
y
b
ri
d
o
m
a
1
2
A
1
im
m
u
n
o
g
lo
b
u
lin
h
e
a
v
y
-c
h
a
in
m
R
N
A
6
/6
4
–
1
5
0
.3
6
3
±
0
.1
3
1
0
.0
4
7
±
0
.0
2
6
*
Z
in
c
fin
g
e
r
p
ro
te
in
9
6
(Z
fp
9
6
)
m
R
N
A
6
/6
3
–
7
0
.0
2
0
±
0
.0
0
0
1
0
.0
9
8
±
0
.0
3
8
**
R
a
t
R
a
s
G
T
P
a
s
e
-
a
c
tiv
a
tin
g
p
ro
te
in
3
/6
2
–
3
0
.2
5
2
±
0
.0
3
0
0
.1
2
1
±
0
.0
1
3
**
B
A
L
B
/c
c
o
n
s
e
rv
e
d
C
H
U
K
m
R
N
A
5
/6
2
–
3
0
.2
0
9
±
0
.0
0
4
0
.4
3
1
±
0
.1
0
4
**
H
.
s
a
p
ie
n
s
T
N
F
a
-s
tim
u
la
te
d
A
B
C
p
ro
te
in
3
/6
2
2
.2
6
8
±
0
.0
7
3
1
.0
9
0
±
0
.0
6
3
**
m
R
N
A
fo
r
a
-a
d
a
p
tin
(C
)
5
/6
2
–
6
0
.0
7
7
±
0
.0
1
0
0
.2
6
4
±
0
.1
3
2
*
M
ito
c
h
o
n
d
ri
a
l
D
N
A
3
/6
2
8
.2
3
9
±
0
.5
9
2
3
.2
2
8
±
0
.2
4
1
*
T
-c
e
ll
tr
a
n
s
c
ri
p
tio
n
fa
c
to
r
N
F
A
T
1
is
o
fo
rm
A
m
R
N
A
3
/6
2
–
3
0
.0
3
4
±
0
.0
0
6
0
.1
0
1
±
0
.0
2
4
*
R
a
t
m
R
N
A
fo
r
ri
b
o
s
o
m
a
l
p
ro
te
in
L
1
8
a
3
/6
2
0
.9
3
2
±
0
.0
5
6
0
.4
7
4
±
0
.0
4
1
*
M
C
H
c
la
s
s
I
h
e
a
v
y
-c
h
a
in
p
re
c
u
rs
o
r
(H
-2
D
(k
))
m
R
N
A
3
/6
2
–
3
2
.6
9
1
±
0
.5
6
1
7
.0
9
3
±
1
.9
0
9
*
L
s
p
-s
m
R
N
A
fo
r
ly
s
o
z
y
m
e
P
2
/6
2
6
.1
1
4
±
0
.1
2
2
3
.1
6
0
±
0
.1
1
6
**
M
C
H
c
la
s
s
I
h
e
a
v
y
-c
h
a
in
p
re
c
u
rs
o
r
(H
-2
K
(k
))
m
R
N
A
3
/6
2
–
6
0
.2
7
5
±
0
.0
5
6
1
.1
2
2
±
0
.5
2
8
*
C
C
1
0
p
ro
te
in
6
/6
2
–
4
8
.5
7
6
±
1
.1
2
2
2
.9
0
3
±
0
.4
1
3
*
C
o
m
p
le
m
e
n
t
c
o
m
p
o
n
e
n
t
C
3
g
e
n
e
,
5
0 e
n
d
4
/6
3
–
1
0
0
.1
4
1
±
0
.0
0
6
0
.8
8
7
±
0
.3
9
4
*
M
ito
c
h
o
n
d
ri
a
l
g
e
n
e
s
fo
r
tr
a
n
s
fe
r
R
N
A
4
/6
2
–
3
4
6
.6
4
±
6
.2
3
7
1
7
.3
8
±
4
.4
4
1
*
46 Expression Profile in Mouse Lung Adenomas Yao et al.
Neoplasia . Vol. 5, No. 1, 2003
M
o
u
s
e
s
u
rf
a
c
ta
n
t
p
ro
te
in
-A
(S
P
-A
)
3
/6
2
0
.9
3
0
±
0
.0
7
9
1
.8
9
0
±
0
.1
1
8
**
v
o
n
E
b
n
e
r
m
in
o
r
s
a
liv
a
ry
g
la
n
d
p
ro
te
in
6
/6
4
–
1
4
0
.1
8
2
±
0
.0
3
0
0
.0
2
7
±
0
.0
3
0
*
R
a
t
m
R
N
A
fo
r
s
u
rf
a
c
ta
n
t
p
ro
te
in
-B
6
/6
2
–
4
1
.4
6
4
±
0
.4
0
1
3
.4
8
8
±
0
.6
6
1
**
*
P
u
lm
o
n
a
ry
s
u
rf
a
c
ta
n
t
p
ro
te
in
S
P
-C
6
/6
2
–
3
0
.3
1
4
±
0
.0
1
4
0
.8
5
1
±
0
.1
0
6
**
*
m
R
N
A
fo
r
s
u
lfa
te
d
g
ly
c
o
p
ro
te
in
-2
4
/6
2
–
3
0
.2
5
9
±
0
.0
5
8
0
.5
4
6
±
0
.1
6
8
*
S
e
ri
n
e
p
ro
te
in
a
s
e
in
h
ib
ito
r
6
(S
P
I6
)
6
/6
2
–
9
0
.0
2
6
±
0
.0
0
5
0
.1
1
0
±
0
.0
7
1
*
a
-1
P
ro
te
a
s
e
in
h
ib
ito
r
2
m
R
N
A
4
/6
6
–
1
3
0
.0
0
8
±
0
.0
0
4
0
.0
9
9
±
0
.0
5
3
*
H
u
m
a
n
m
R
N
A
fo
r
K
IA
A
0
1
8
3
5
/6
2
–
5
0
.0
5
0
±
0
.0
0
4
0
.1
6
3
±
0
.0
6
6
*
H
u
m
a
n
m
R
N
A
fo
r
K
IA
A
0
1
8
7
6
/6
2
–
5
0
.1
2
6
±
0
.0
0
6
0
.4
0
4
±
0
.1
0
0
**
*
H
o
m
o
lo
g
o
f
D
.
m
e
la
n
o
g
a
s
te
r
fli
g
h
tle
s
s
I
6
/6
2
–
1
9
0
.0
5
4
±
0
.0
1
1
0
.3
8
8
±
0
.2
8
6
*
C
Y
P
2
C
4
0
4
/6
3
–
9
0
.0
0
3
±
0
.0
0
1
0
.0
1
6
±
0
.0
0
8
*
R
IK
E
N
c
D
N
A
2
5
0
0
0
0
2
L
1
4
g
e
n
e
5
/6
2
–
4
0
.0
9
0
±
0
.0
1
1
0
.2
5
8
±
0
.0
6
8
**
R
IK
E
N
c
D
N
A
5
7
3
0
4
0
3
B
1
0
g
e
n
e
3
/6
2
0
.1
8
3
±
0
.0
0
3
0
.3
8
6
±
0
.0
6
6
*
B
ra
in
c
D
N
A
,
c
lo
n
e
M
N
C
b
-5
7
0
4
6
/6
2
–
1
0
0
.2
8
3
±
0
.1
3
3
1
.5
5
3
±
1
.0
4
0
*
A
d
u
lt
m
a
le
te
s
tis
c
D
N
A
4
/6
2
0
.0
5
0
±
0
.0
0
7
0
.1
1
2
±
0
.0
1
6
**
0
-D
a
y
n
e
o
n
a
te
s
k
in
c
D
N
A
6
/6
5
–
1
6
0
.0
1
3
±
0
.0
0
1
0
.1
3
0
±
0
.0
5
4
**
1
0
-D
a
y
e
m
b
ry
o
c
D
N
A
6
/6
2
–
4
0
.6
4
1
±
0
.0
9
4
1
.6
4
1
±
0
.5
2
7
**
M
u
s
m
u
s
c
u
lu
s
p
ro
lin
e
4
-h
y
d
ro
s
y
la
s
e
a
-1
p
o
ly
p
e
p
tid
e
(P
4
h
a
1
)
6
/6
2
–
4
0
.1
0
0
±
0
.0
1
7
0
.3
0
7
±
0
.0
9
4
*
M
.
m
u
s
c
u
lu
s
s
im
ila
r
to
K
IA
A
1
7
1
1
5
/6
2
–
3
0
.2
0
0
±
0
.0
2
9
0
.5
6
2
±
0
.1
0
5
**
*
M
o
u
s
e
D
N
A
s
e
q
u
e
n
c
e
fr
o
m
c
lo
n
e
R
P
2
3
-3
9
4
0
9
o
n
c
h
ro
m
o
s
o
m
e
1
1
5
/6
2
–
4
1
.2
7
6
±
0
.3
8
4
3
.5
6
2
±
0
.9
3
6
**
M
.
m
u
s
c
u
lu
s
h
y
p
o
th
e
tic
a
l
p
ro
te
in
M
G
C
2
5
8
3
6
5
/6
2
–
4
0
.0
2
1
±
0
.0
0
4
0
.0
7
1
±
0
.0
1
9
**
H
.
s
a
p
ie
n
s
c
h
ro
m
o
s
o
m
e
1
8
,
c
lo
n
e
R
P
1
1
-7
4
9
G
1
3
/6
2
0
.6
1
5
±
0
.2
1
0
1
.8
3
5
±
0
.5
2
2
*
L
R
G
1
#
6
/6
2
–
4
0
.0
2
2
±
0
.0
0
5
0
.0
6
2
±
0
.0
1
4
**
*
L
R
G
2
#
5
/6
3
–
7
0
.0
7
2
±
0
.0
0
7
0
.3
7
0
±
0
.1
0
4
**
L
R
G
3
#
6
/6
2
–
4
0
.0
1
3
±
0
.0
0
3
0
.0
3
7
±
0
.0
1
3
*
L
R
G
4
#
6
/6
2
–
7
0
.0
1
8
±
0
.0
1
2
0
.0
8
2
±
0
.0
3
2
**
L
R
G
5
#
6
/6
3
–
1
6
0
.0
2
8
±
0
.0
0
0
2
0
.3
9
1
±
0
.1
5
4
**
*
L
R
G
6
#
6
/6
2
–
8
0
.0
8
2
±
0
.0
4
8
0
.4
9
2
±
0
.1
6
5
**
L
R
G
7
#
6
/6
5
–
1
3
0
.0
0
6
±
0
.0
0
2
0
.0
6
5
±
0
.0
2
3
**
*
*P
<
.0
5
.
**
P
<
.0
1
.
**
*P
<
.0
0
1
.
y P
u
ta
tiv
e
id
e
n
tit
y
b
a
s
e
d
o
n
h
ig
h
d
e
g
re
e
s
o
f
h
o
m
o
lo
g
y
w
ith
k
n
o
w
n
g
e
n
e
s
(s
e
e
R
e
s
u
lts
).
z I
n
c
id
e
n
c
e
is
th
e
n
u
m
b
e
r
o
f
tu
m
o
rs
h
a
d
c
h
a
n
g
e
s
o
u
t
o
f
n
u
m
b
e
r
o
f
tu
m
o
rs
te
s
te
d
.
x R
a
n
g
e
o
f
fo
ld
in
c
re
a
s
e
o
r
re
d
u
c
tio
n
is
c
a
lc
u
la
te
d
in
in
d
iv
id
u
a
l
tu
m
o
rs
to
c
o
n
tr
o
l
tis
s
u
e
s
.
{ S
ta
tis
tic
a
lly
d
iff
e
re
n
t
fr
o
m
n
o
rm
a
l
c
o
n
tr
o
ls
.
#
T
h
e
g
e
n
e
s
h
a
v
e
n
o
m
a
tc
h
e
s
in
N
C
B
I
G
e
n
B
a
n
k
.
W
e
n
a
m
e
d
th
e
g
e
n
e
s
a
s
L
u
n
g
tu
m
o
r–
R
e
la
te
d
G
e
n
e
s
(L
R
G
).
Neoplasia . Vol. 5, No. 1, 2003
Expression Profile in Mouse Lung Adenomas Yao et al. 47
T
a
b
le
2
.
P
a
rt
ia
l
S
e
q
u
e
n
c
e
s
o
f
th
e
U
n
k
n
o
w
n
G
e
n
e
s
C
o
n
fir
m
e
d
w
ith
D
iff
e
re
n
tia
l
E
x
p
re
s
s
io
n
in
M
o
u
s
e
L
u
n
g
A
d
e
n
o
m
a
s
.
G
e
n
e
b
p
S
e
q
u
e
n
c
e
L
R
G
1
5
6
6
G
T
T
T
T
G
C
C
T
A
A
G
T
G
C
T
G
A
C
T
T
C
T
T
T
A
T
T
G
A
C
T
C
C
T
T
T
A
G
A
G
A
A
A
G
T
T
A
T
T
A
T
G
A
C
C
A
A
T
A
C
A
T
A
C
T
C
C
A
T
G
T
T
A
A
T
C
C
T
G
T
C
C
C
T
C
A
A
G
T
G
T
T
T
C
T
T
T
A
G
G
C
A
T
T
G
A
T
A
T
T
A
T
G
G
T
A
C
A
T
T
C
T
C
T
A
C
C
A
T
A
A
T
A
C
T
T
C
T
A
A
T
C
T
G
A
C
T
T
T
C
C
T
T
C
A
G
G
A
T
G
A
T
G
G
A
G
T
T
A
T
G
A
A
T
T
T
T
C
C
C
C
T
T
T
A
T
T
A
A
A
A
C
G
A
G
G
C
A
A
G
G
T
G
G
T
G
C
A
T
G
C
C
T
G
T
A
A
T
C
A
T
A
G
C
A
C
C
T
A
G
T
A
G
G
C
A
A
G
G
G
T
A
G
A
A
A
G
A
T
G
A
T
G
A
A
T
T
T
G
A
A
G
C
C
A
G
T
T
T
G
G
C
C
T
T
A
T
A
T
A
A
T
A
A
A
G
C
C
T
C
A
T
G
T
G
G
A
A
A
A
A
C
C
G
T
G
C
A
G
G
C
A
A
G
G
C
T
G
A
G
G
A
T
A
T
A
G
T
T
C
A
G
T
G
G
T
A
A
C
G
C
A
C
T
T
G
C
T
T
A
A
G
T
G
T
G
C
C
C
C
A
G
G
T
C
T
A
A
T
A
C
G
A
G
A
A
A
A
C
A
A
A
G
C
A
T
T
T
T
T
G
T
T
A
C
T
A
C
T
G
G
T
T
G
T
T
G
G
G
C
A
G
G
C
G
A
G
G
T
G
A
C
T
T
G
G
T
G
G
A
T
G
T
G
A
G
T
C
T
T
G
C
T
T
T
C
A
A
A
C
C
T
G
A
T
C
A
C
T
C
A
G
T
T
C
A
A
T
A
T
C
T
T
G
G
A
T
C
C
A
T
A
T
A
G
C
A
G
A
A
A
G
T
G
C
A
A
G
T
T
G
T
T
C
T
A
T
G
A
T
T
C
G
C
A
T
T
A
C
T
G
G
G
C
G
T
G
T
G
T
G
C
T
C
T
C
T
C
A
T
G
C
A
C
A
C
A
C
A
G
G
T
G
T
A
A
A
T
A
A
A
T
G
G
A
L
R
G
2
3
1
9
G
A
C
A
T
A
T
G
A
C
A
A
G
A
C
A
G
A
A
A
G
C
C
A
G
A
G
A
C
A
A
G
A
G
A
T
T
C
A
G
G
C
T
T
G
T
T
T
T
C
A
T
T
A
T
G
T
T
G
C
C
T
T
A
G
T
C
T
C
C
C
T
A
G
C
A
C
T
A
A
T
A
A
A
G
G
C
C
C
T
G
A
G
A
G
A
A
C
T
A
C
T
T
T
A
A
T
C
T
C
C
T
C
C
A
G
G
G
G
T
G
G
C
A
C
T
C
C
C
A
A
T
G
A
C
C
T
A
A
T
C
A
C
C
T
T
C
A
T
T
A
A
G
C
C
A
C
G
C
C
T
C
T
T
A
A
A
A
G
C
C
C
T
G
C
A
C
A
A
T
C
C
T
G
G
A
A
C
C
C
A
G
C
C
T
T
C
T
A
G
G
T
C
A
T
G
A
C
A
A
T
T
T
G
A
T
G
G
A
T
C
C
C
C
T
C
G
T
A
C
A
C
C
A
G
A
C
A
G
N
G
G
T
G
T
A
C
G
A
C
C
A
C
C
A
T
C
T
G
G
C
C
C
C
T
T
C
C
A
T
G
G
A
G
A
A
C
A
T
A
C
A
G
A
C
T
T
C
A
G
A
A
A
A
C
A
C
T
T
G
G
G
C
A
G
C
G
G
A
C
A
G
G
A
C
C
C
A
C
L
R
G
3
3
7
8
T
T
T
A
T
G
G
T
G
C
C
A
C
C
T
T
T
T
C
C
A
G
A
G
A
G
G
A
G
T
C
C
G
G
C
T
A
G
G
G
T
G
T
C
T
G
G
A
G
C
C
T
A
A
A
C
A
A
C
C
A
G
G
C
T
G
C
T
G
G
G
A
G
A
G
G
C
A
G
C
A
A
G
G
G
G
A
G
A
G
A
A
G
G
C
G
A
A
G
G
G
C
A
G
G
A
A
G
T
T
G
T
C
A
G
C
C
T
G
A
G
T
C
A
C
A
G
G
G
T
G
C
A
G
G
A
G
G
G
G
T
C
T
T
G
G
A
G
G
G
C
T
G
G
C
T
G
C
C
C
T
C
C
C
T
T
C
T
C
A
G
G
G
C
A
G
C
T
G
T
G
C
C
C
A
T
T
T
C
A
C
C
G
T
C
T
G
T
G
T
C
C
C
A
C
C
C
C
T
A
C
C
C
A
A
G
T
C
C
T
G
T
G
T
T
T
G
A
C
A
G
C
A
G
T
T
T
C
C
A
C
T
T
G
T
C
A
T
G
G
A
A
A
A
G
C
C
T
G
T
C
T
C
G
G
C
T
T
T
G
G
G
T
G
T
G
T
G
C
A
G
A
T
T
C
G
G
T
G
T
C
C
C
T
G
A
G
A
C
T
G
A
G
C
T
G
C
A
G
C
C
C
A
T
C
A
A
G
G
G
C
A
G
A
G
C
C
A
C
T
G
G
A
C
T
T
C
C
A
A
C
C
T
C
T
G
G
A
T
G
G
A
C
C
T
G
G
G
G
A
C
T
A
A
A
C
T
A
T
G
T
G
C
C
A
T
G
A
L
R
G
4
5
7
9
A
C
C
A
T
C
C
A
A
G
T
G
T
A
A
G
C
C
A
T
T
T
T
T
G
A
T
A
A
C
T
A
C
A
C
A
T
T
T
G
T
T
T
A
C
A
T
C
C
T
A
A
G
A
A
C
T
T
T
A
C
A
T
C
A
A
T
T
A
T
C
T
T
A
C
T
T
C
A
T
G
C
T
A
A
C
A
T
C
A
C
T
G
G
C
T
G
G
G
A
T
A
T
A
T
G
C
T
T
T
T
A
T
T
A
A
T
T
C
C
A
T
T
C
C
A
A
A
C
A
T
G
A
G
A
A
A
A
C
T
T
A
G
C
T
A
C
G
G
A
G
T
C
C
A
T
T
T
T
G
T
A
T
A
A
G
G
T
C
A
C
A
C
G
G
A
C
A
G
G
T
A
T
A
A
G
C
T
G
T
A
T
C
A
A
T
G
T
T
T
A
A
T
G
T
C
T
A
T
C
T
T
G
A
G
G
C
A
G
C
A
T
C
C
C
C
A
C
T
T
G
G
C
T
C
A
G
A
T
G
C
C
C
A
C
C
T
C
A
G
G
A
G
C
T
C
G
T
G
A
G
G
C
A
G
A
T
G
T
G
G
G
C
C
T
G
T
G
C
T
G
G
G
C
C
C
T
C
A
C
A
G
A
G
T
C
T
C
T
T
G
G
A
G
C
A
G
T
A
G
G
C
A
C
T
G
G
C
C
A
T
A
G
T
T
T
G
C
C
C
T
C
T
T
T
T
T
A
G
C
A
T
T
T
A
C
A
A
C
T
G
C
T
A
T
T
A
T
G
G
C
G
T
C
T
A
G
T
G
G
C
A
G
G
G
T
A
T
C
A
G
C
T
C
T
A
A
G
A
T
T
A
T
A
T
T
T
C
T
T
A
T
T
A
A
A
T
C
C
T
T
A
A
A
T
G
A
T
A
G
A
G
C
T
T
T
T
A
T
G
A
T
C
T
T
G
T
T
T
A
T
A
A
G
T
T
G
A
G
G
A
T
T
A
A
A
T
A
G
A
A
C
T
C
C
C
C
T
C
C
C
C
T
T
T
T
T
T
T
T
C
A
G
C
C
C
A
N
G
G
T
T
G
T
T
T
G
A
T
A
G
A
G
G
T
G
T
G
T
G
T
A
G
G
T
G
T
G
T
T
T
A
A
T
G
T
A
A
A
T
T
A
C
C
C
A
T
T
T
T
C
T
T
T
T
T
T
A
T
A
C
A
A
A
T
C
T
G
G
A
C
C
T
C
C
T
T
T
T
T
C
C
C
T
C
C
C
T
T
L
R
G
5
4
5
4
T
T
T
G
C
C
C
A
A
T
G
T
T
C
C
A
A
G
C
C
G
A
A
A
A
G
T
G
T
G
T
C
A
T
C
A
T
G
A
A
G
A
G
A
T
G
G
C
A
C
T
T
A
T
T
T
T
C
A
G
A
G
C
T
G
A
G
G
T
G
C
C
C
G
G
G
A
G
A
A
C
T
G
A
A
C
A
T
T
C
T
C
T
G
A
C
A
A
C
C
A
G
G
A
T
G
C
C
T
C
G
G
G
G
C
A
A
T
G
G
A
T
T
C
T
G
A
T
T
G
G
A
T
A
G
C
T
G
G
C
C
A
C
A
G
G
C
T
G
C
G
A
A
A
A
C
C
A
T
G
C
A
G
G
A
A
A
A
T
C
T
C
A
G
G
G
G
G
G
C
T
T
G
C
T
A
T
G
T
G
G
T
C
T
A
T
G
G
T
T
A
T
C
T
T
G
G
C
A
G
G
A
A
A
C
C
A
G
G
A
C
C
T
G
G
G
G
C
T
G
A
A
C
A
C
A
G
T
A
G
A
A
A
T
G
G
G
G
T
G
T
T
T
T
C
A
T
A
A
T
T
A
T
C
C
C
T
G
T
T
G
G
G
T
G
C
C
A
T
T
G
A
G
C
A
C
A
T
A
C
A
A
G
T
C
T
T
T
A
G
A
T
G
C
C
A
C
A
C
G
C
A
C
T
G
A
A
C
A
T
A
C
A
C
C
T
C
T
C
T
G
G
T
C
T
C
C
A
G
T
G
C
A
C
C
G
T
A
T
C
A
G
G
C
T
T
G
G
G
A
C
T
C
A
C
T
G
T
A
G
G
C
A
G
A
C
A
T
T
A
G
C
A
G
A
T
C
G
C
G
T
C
C
T
T
C
A
A
T
G
C
T
T
G
G
C
C
T
C
G
T
G
T
C
T
A
T
G
C
A
G
T
A
C
T
T
A
G
C
A
G
T
G
G
T
T
A
G
A
C
A
C
T
G
C
C
A
A
G
A
G
T
C
T
L
R
G
6
6
5
4
G
G
A
C
T
A
G
T
C
C
G
A
G
T
T
T
T
T
T
T
T
T
C
T
T
T
T
T
T
T
T
T
T
T
T
G
A
G
A
G
T
T
G
T
G
G
T
T
C
T
C
C
T
G
G
C
G
A
T
A
A
T
T
T
C
T
C
T
C
A
C
A
C
T
T
A
T
A
C
T
T
C
C
T
T
T
G
A
A
G
A
T
G
T
C
T
G
C
A
T
T
T
T
C
A
C
C
T
C
A
T
T
T
C
T
C
C
G
A
G
G
A
C
A
C
T
G
T
T
T
T
A
C
A
G
G
A
C
A
C
A
G
A
A
C
T
A
C
A
G
G
G
T
G
G
C
A
T
T
C
C
T
T
C
C
C
T
C
C
C
C
T
T
T
C
A
G
C
A
C
C
T
T
T
G
G
G
A
T
T
T
C
A
C
C
C
C
A
T
C
C
T
T
C
A
T
T
G
G
C
T
A
C
C
A
C
T
G
C
G
A
C
C
A
T
C
C
G
A
C
C
C
T
G
A
G
G
T
C
G
T
C
A
G
C
T
C
G
T
C
T
C
A
C
T
G
T
T
C
T
C
C
A
C
T
G
A
C
C
A
G
C
C
C
T
T
C
T
T
G
T
C
T
T
C
C
T
T
T
G
T
G
C
T
G
T
T
T
T
C
C
A
G
A
C
T
C
C
A
T
C
A
G
A
C
T
C
T
C
A
C
C
C
C
C
T
T
C
C
C
A
G
T
C
T
T
C
A
C
T
G
G
T
T
T
G
G
A
T
T
G
A
T
G
T
G
T
C
C
A
G
G
A
G
T
A
G
G
T
C
T
T
T
G
T
A
T
A
A
G
G
A
A
C
C
G
C
C
C
G
T
T
C
T
G
C
T
T
G
G
A
C
T
C
C
G
C
T
G
T
T
T
C
T
T
G
G
A
T
C
T
G
G
G
G
G
T
T
G
G
T
A
T
T
T
T
C
A
T
T
A
G
C
T
G
T
A
A
A
A
G
C
T
T
C
T
G
G
T
C
T
T
T
A
T
G
C
A
T
T
C
A
T
G
T
C
T
A
C
A
T
G
T
A
G
C
A
C
C
C
C
A
C
C
C
C
A
A
A
C
A
A
G
T
C
C
T
C
T
G
C
A
T
C
T
C
C
T
T
T
A
T
G
A
A
T
G
C
T
A
A
A
A
C
A
C
A
T
T
T
T
T
T
A
A
G
A
T
T
T
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
T
G
G
T
G
G
G
A
T
G
C
A
C
C
C
T
G
A
A
A
G
T
C
T
A
A
A
A
G
G
A
G
T
C
T
G
A
T
C
C
T
C
T
G
G
G
G
C
T
G
G
C
T
T
A
A
A
G
T
T
T
A
C
C
C
C
C
C
C
C
L
R
G
7
6
1
7
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
C
T
T
T
T
T
T
C
T
C
T
T
C
T
C
T
T
C
T
C
T
T
C
T
C
T
T
C
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
T
C
T
T
T
C
T
C
C
C
C
A
T
C
T
A
G
G
A
T
A
C
C
A
T
C
C
T
C
T
C
C
G
T
G
T
T
C
T
C
C
A
T
G
C
A
G
C
T
C
A
G
T
G
G
G
C
A
C
T
T
G
G
C
A
T
T
T
C
C
T
T
C
A
G
C
C
C
C
G
T
T
C
T
G
T
C
C
T
T
C
C
T
G
A
T
A
T
A
T
G
G
C
C
G
A
G
A
C
A
A
T
C
C
A
C
A
A
T
T
A
T
T
T
G
C
T
C
C
C
A
T
G
A
C
C
T
C
T
G
T
T
C
A
G
A
A
C
T
A
A
A
T
T
A
T
A
A
T
A
A
A
C
C
C
C
T
C
C
A
T
T
T
T
A
T
A
T
A
T
T
T
G
A
G
C
C
C
A
A
A
T
T
T
C
C
A
G
T
T
T
C
T
C
A
G
A
A
T
A
T
A
A
A
T
G
T
A
A
A
T
G
C
A
A
G
T
A
G
G
A
C
C
A
A
A
A
G
A
G
A
G
A
G
A
T
T
T
A
A
A
T
C
G
A
G
T
T
T
A
T
T
A
A
G
G
G
G
G
A
A
C
T
A
A
T
T
C
A
G
C
C
T
G
G
C
C
G
G
T
G
A
T
C
T
T
A
T
G
A
A
G
A
G
A
C
T
G
G
T
A
C
A
T
G
C
A
G
A
G
A
G
G
A
G
A
T
G
A
G
C
T
C
C
A
G
G
G
A
A
A
C
G
A
C
A
G
A
G
G
A
A
A
G
A
C
G
A
G
C
C
T
G
A
G
G
T
G
A
G
G
T
G
G
T
C
A
A
G
G
A
A
A
C
A
G
C
C
T
T
G
C
C
A
G
T
G
C
C
A
C
G
C
C
C
A
T
G
C
A
C
A
G
C
T
C
C
C
T
C
C
T
G
G
A
A
C
T
A
T
A
A
G
A
A
A
A
C
G
T
G
T
T
T
T
T
G
T
A
T
T
C
G
G
T
T
C
T
T
G
G
A
G
A
G
G
C
C
T
T
T
G
C
A
A
A
C
T
A
A
C
A
G
T
C
T
T
C
C
A
T
G
G
G
A
A
T
G
G
G
T
T
A
C
C
T
T
T
A
C
C
C
T
T
A
C
C
C
T
T
T
T
C
C
T
T
T
T
C
C
T
T
T
T
C
48 Expression Profile in Mouse Lung Adenomas Yao et al.
Neoplasia . Vol. 5, No. 1, 2003
was found to be highly homologous (>98%) to mouse
neuronal GEF.
Discussion
In the present study, we used CCLS to identify differentially
expressed genes in mouse lung adenomas. The CCLS
method allows one to define differentially expressed genes,
based on competitive hybridization between normal lung
RNA and RNA derived from lung adenomas, in a non-
selective manner and allows one to readily clone differ-
entially expressed genes. There are many advantages in the
use of CCLS to determine gene expression changes in
cancer. For example, expression differences for both known
and novel genes can be detected. Because the cDNA library
is not normalized to ensure approximately equal representa-
tion of polyA+ RNA sequences, detection frequencies of
differentially expressed genes can be determined, indicating
the relative frequency of mRNA expression in the normal
lung tissue. Additionally, in-depth sampling of gene expres-
sion changes for more than 100,000 clones is possible. Al-
though CCLS is laborious and time-consuming, screening
data are extensive and allow for the further characterization
and functional analysis of unknown genes and examination
of the potential roles of known genes in lung tumorigenesis.
Some disadvantages of CCLS also exist. The use of CCLS
methodology that employs a normal mouse lung cDNA
library yields a number of implications. First, if a gene that is
Figure 4. Characterizations of FLJ11240 hypothetical protein, and neuronal guanine nucleotide exchange factor. (A ) The sequence alignments of FLJ11240
hypothetical protein and neuronal guanine nucleotide exchange factor (Ngef ) with human counterpart proteins. (B ) RT -PCR verification of differential
expressions of FLJ11240 hypothetical protein and neuronal guanine nucleotide exchange factor. ‘‘N’’ represents the normal mouse lung tissue; ‘‘T’’ represents
the MNU- induced mouse lung adenomas. GAPDH was applied as an internal control to determine the amount of template in each reaction.
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found in tumor tissue were not expressed at all in the normal
lung, it would not be detected in this study. Secondly, genes
that are expressed at very low levels in normal lung were
probably missed using this method. Thirdly, because the
cDNA library is not normalized, clones associated with sig-
nificantly overexpressed genes may be repeatedly selected.
Thus, there were hundreds of independent clones identi-
fied that proved by sequencing to be either surfactants or
CC10.
Sixty- five genes were found to be differentially ex-
pressed in lung adenomas when compared to normal lung.
Nineteen genes were underexpressed and 46 were over-
expressed. Seven clones do not match any of the known
genes in the NCBI sequence database, whereas 58 had
high homology to known genes. For most of the genes, the
changes were highly reproducible; thus, 37 of 49 genes
displaying overexpression in tumors demonstrated such
overexpression in at least two or three of the adenomas.
Moreover, 24 of 37 genes were overexpressed at least
three- fold and 12 of 37 at least five- fold. Similarly, 10 of 19
underexpressed genes were underexpressed in at least two
or three of the adenomas and 6 of 19 were underexpressed
at least three- fold in adenomas. Although some of the
genes appear to be mechanistically more relevant to the
cancer process or are more obvious candidate targets for
therapy (see Discussion below), any of the defined genes
may be candidate markers for early detection of lesions and
as potential endpoint biomarkers. Known genes found to be
differentially expressed in lung adenomas including 45S
pre-rRNA, pancotin, a -globin, b -globin, fibrinogen A a -
chain, paroxanase, cysteinyl - tRNA synthetase, homolog of
D. melanogaster flightless I gene, von Ebner minor salivary
gland protein, and TNFa -stimulated ABC protein. Although
the role of these genes in mouse lung tumorigenesis is still
unknown, they are candidate biomarkers for lung tumori-
genesis and potential targets for chemoprevention studies.
Many of the differentially expressed genes were detected
reproducibly and were highly altered in tumors versus nor-
mal parenchyma including JAK-1, zinc finger 96, a -1
protease inhibitor, and homolog of D. melanogaster flight-
less I gene.
Three particularly intriguing overexpressed genes code
for the kinases: ERK-1, JAK-1, and CHUK. All three genes
are overexpressed in at least 67% of adenomas, and JAK-1
levels are overexpressed almost five- fold in adenomas.
Members of the various kinase families are particularly
appealing for chemotherapy studies using mouse lung tumor
model because small molecule inhibitors have been devel-
oped against this family of enzymes. ERK-1 belongs to the
MAK kinase family and is a component of signaling path-
ways that influences cellular proliferation and differentia-
tion, while JAK-1 is a member of the intracellular tyrosine
kinase family (Janus kinases), and activation of JAKs is
the initial step in cytokine signaling. Studies have shown
that ERK activation increased 15- fold, whereas ERK ex-
pression levels were only 1.3- fold higher in prostate
cancer [19]. CHUK contains a serine–threonine kinase
catalytic domain and may be targeted to a helix– loop–
helix and/or a leucine zipper transcription factor [20].
CHUK links kinase cascades to NF-kB activation [21].
RasGAP was downregulated and both ERK-1 and JAK-1
were upregulated in mouse lung tumors. RasGAP, which is
downregulated in adenomas, is a ubiquitous 120-kDa pro-
tein that hydrolyzes GTP bound to p21Ras [22,23]. Under-
expression of RasGAP, which should increase the levels of
Ras proteins in the activated state, and overexpression of
ERK-1 appear to be crucial to Ras–RasGAP cycling–Raf-
1–MAPK kinase signal transduction in mouse lung tumor
development. Studies show that a -adaptin interacts with
GHR and mediates endocytosis of GHR [24] upon hormone
stimulation. The interaction of Shc with a -adaptin is also
involved in receptor endocytosis [25]. Our data showed that
a -adaptin was overexpressed in 80% of mouse lung
adenomas ( five of six).
NFAT1, CA150, CHUK, and zinc finger protein 96 were
overexpressed in 50%, 67%, 83%, and 100% of lung tumors,
respectively. These four genes play crucial roles in signal
transduction and gene expression. NFAT1 orients the two
subunits of AP-1, c-Jun, and c-Fos on DNA through direct
protein–protein interaction to regulate transcription [26,27].
Evidence suggests that CA150, a nuclear protein associated
with the human RNA polymerase II holoenzyme, plays a role
in the regulation of cellular transcriptional processes [28].
The functions of CA150 in the mouse have not as yet been
reported. CHUK contains a serine–threonine kinase cata-
lytic domain and may be targeted to helix– loop–helix and/or
leucine zipper transcription factors [20]. CHUK links kinase
cascades to NF-kB activation [21]. The zinc finger motif is
generally present in most transcription factors that regulate
gene expression. Overexpression of NFAT1, CA150, CHUK,
and the zinc finger protein 96 in mouse lung tumor cells is
likely to facilitate DNA transcription upon growth stimulation
during tumor development.
The result showing a decrease in cyr61 appears to
contradict the explanation that it is a factor that will stimulate
tumor growth. Cyr61 is a secreted, cysteine-rich, heparin-
binding protein encoded by a growth factor– inducible early
gene, which acts as an extracellular, matrix -associated
signaling molecule promoting the adhesion of endothelial
cells through interaction with integrin aVb3 [29–31]. Studies
suggest that cyr61 is an angiogenic inducer that promotes
tumor growth and vascularization through integrin aVb3–
dependent pathways [32]. We found that cyr61 was under-
expressed in five of six lung tumors.
Three genes that encode metabolizing enzymes were
differentially expressed in mouse lung tumors. CA IV and
ALDH II were downregulated in 50% and 83% of tumors,
respectively. CYP2C40 was overexpressed in 67% of tu-
mors. CA IV is a glycoprotein associated with cell mem-
branes in lung and kidney [33,34]. Altered expression of
various CA isozymes has been observed in a variety of tumor
types. CA, an NADPH-dependent enzyme, has many func-
tions: elimination of CO2 and metabolites, pH regulation, and
participation in membrane transport events during active cell
growth [35]. ALDH II is a member of the ALDH family and
plays a role in ethanol detoxification [36]. Similar to other
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p450 enzymes, CYP2C40 plays an important role in bio-
activation and detoxification of certain hepatoxins.
In this study, sulfated glycoprotein-2 (clusterin) was
overexpressed in more than 67% of lung tumors. Clusterin is
a widely expressed, well -conserved, secreted glycopro-
tein that inhibits apoptosis. Secreted proteins such as
clusterin become particularly attractive candidate proteins
as biomarkers of cancer in serum. Recent studies indicate
that overexpression of clusterin confers cellular protection
against heat shock and oxidative stress [37] and exogenous
clusterin reduces the sensitivity of cells to TNF [38].
MHC class I, immunoglobulin, and complement compo-
nents are involved in immune surveillance [39]. In this
study, both the MHC class I heavy-chain precursors, H-
2D(k) and H-2K(k), are upregulated in tumors. Alterations
in expression of these genes may reflect differences in the
numbers of lymphoid cells observed in tumors as contrasted
with normal lung parenchyma. Complement C3 is also up-
regulated, whereas 12A1 immunoglobulin heavy chain is
downregulated.
A number of genes that are commonly expressed in
normal lung parenchyma were overexpressed or underex-
pressed in lung adenomas. We have also shown that
surfactant -associated proteins (SPs) A, B, and C are up-
regulated in three of six (50%), six of six (100%), and six
of six (100%), whereas CC10 was downregulated in all
lung adenomas examined. These results suggest that most
of the lung adenoma cells were derived from Type II cells
instead of Clara cells. Alternatively, altered expression of
these genes may have functional implications. For exam-
ple, CC10 may function to bind to calcium, proteins, or
other ligands and may be an important immunomodulatory
and anti - inflammatory protein [40,41]. Overexpression of
CC10 cDNA in the NSCLC cell line A549 markedly re-
duces its invasiveness. CC10-transfected cell lines also
exhibit decreased adhesiveness to fibronectin [42]. These
results support the conclusion that loss of CC10 may
contribute to carcinogenesis. SP-A, SP-B, and SP-C,
are known to be required for optimal surfactant function
[43]. The functional significance of these proteins is un-
known. Studies have shown that SP mRNA are present in
all lung tumors, with SP-A, SP-B, and SP-C being co-
expressed in 10 of 12 (83%) adenomas and four of five
(80%) carcinomas [44].
There is a possibility that some of the differentially
expressed genes are due to differences in the density of
mouse Type II cells or Clara cells in normal lungs versus and
in lung adenomas with respect to amounts of relative to
stromal and other contaminating cells. We have not been
successful in isolating pure Type II cells or Clara cells from
normal surrounding lungs of the animals bearing adenomas.
Furthermore, numerous steps and treatments required for
the current methodology available for isolating these cells
would not make the isolated cells suitable control cells for
lung adenomas that did not undergo such a process for gene
expression profiling studies.
As was mentioned in the Introduction, one of the
strengths of the CCLS technique is its ability to allow the
identification and cloning of unknown or minimally des-
cribed genes. Thus, in addition to the better known genes
described above, an additional seven unknown genes were
described as being overexpressed in the majority of lung
adenomas. In fact, most of these genes were overex-
pressed at least three- fold. Two of the genes were further
characterized by extensive sequencing and comparison of
both mouse and human cDNA: a hypothetical protein
(FLJ11240) and a GEF homologue (Figure 4). FLJ11240
hypothetical protein was found to have partial homology
with a peptidase, E1–E2 ATPase, His kinase, and Ppx/
GppA phosphatase when searching the Protein-BLAST
database (NCBI, NIH). The GEF gene was found to be
highly homologous (>98%) to mouse neuronal GEF. GEFs
have been shown to play important roles in the Ras sig-
naling pathway, which is frequently activated by the binding
of Ras to Raf protein kinases, Type I phosphatidylinositol -
3 (PI3) kinases, or Ral -specific guanine nucleotide ex-
change factors (RalGEFs) [13]. RalGEFs interact with Ras
to form the GTP-bound state of the Ral family GTPases,
leading to enhanced transcription of c- fos, cyclin D1, and
genes containing the TATA-binding protein promoter [14–
17]. Recently, activation of the RalGEF pathway has been
shown to promote tumor metastasis [18]. This result
suggests that overexpression of the neuronal GEF gene
is associated with lung carcinogenesis in mice. These
results show the strength of this approach for identifying
unknown or minimally characterized genes with altered
expression.
Finally, several genes differentially expressed, observed
in this study using the CCLS method, are also found to be
differentially expressed in mouse lung tumors through
immunohistochemistry. For example, Mason et al. [45 ] re-
ported increased expression of SP-A and SP-C in mouse
lung adenomas and the lack of expression of CC10 in mouse
lung adenomas regardless of morphology (solid or papillary)
using immunohistochemistry. Another report by Ramak-
rishna et al. [46] found that expression of Erk1/2 was
increased in mouse lung tumors using immunoblotting
method. These reports provide further confirmation of our
results using a different methodology.
The genes identified in this study can be employed in a
variety of ways: 1) for use as early detection markers for
lung lesions in the A/J model; 2) to compare the gene
expression changes observed in the A/J model compared
with human adenocarcinomas; 3) for basic understanding
of the cancer process; 4) to help define potential molecular
targets, which can be tested in this highly reproducible lung
tumor model; and 5) to serve as potential modulatable
biomarkers, which can be employed in screening for
potential agents or in determining the efficacy of those
agents.
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